Astodrimer Sodium Nasal Spray versus Placebo in Non-Hospitalised Patients with COVID-19: A Randomised, Double-Blinded, Placebo-Controlled Trial
Astodrimer nasal spray reduces viral burden and accelerates viral clearance, especially in older populations, and is well tolerated.
Authors
- Jeremy Ra Paull (ORCID: https://orcid.org/0000-0002-9981-421X)
- Kapila Ranasinghe
- G R Kinghorn (ORCID: https://orcid.org/0000-0001-6608-5076)
- Isaac John (ORCID: https://orcid.org/0000-0003-2856-6180)
- Meera Nadir
- Stephen Winchester (ORCID: https://orcid.org/0000-0003-3377-3256)
- Alex Castellarnau
- Xavier Masramón
- Kashif Jabbar
Institutions
- National Health Service (GB)
- Royal Holloway University of London (GB)
- Royal Hallamshire Hospital (GB)
- Starpharma (Australia) (AU)
- Ashford and St Peter's Hospitals NHS Foundation Trust (GB)
- University of Sheffield (GB)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2024-09-06
- DOI
- https://doi.org/10.3390/pharmaceutics16091173
- Citations
- 2
- Primary Topic
- Infection Control and Ventilation
- Type
- article
- Field-Weighted Citation Impact
- 0.84